Loss of heterozygosity of PTEN has been reported in about 40%–50% of breast cancer patients, and about 5%–10% of patients with breast cancer have PTEN mutations, most commonly frameshift mutations, resulting in PTEN functional loss (13, 15, 18). This evidence concerns the gene PTEN and breast cancer.